NCT00001031View on ClinicalTrials.gov

A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

296

Participants

Timeline

Start Date

Not specified

Study Completion Date

December 31, 1997

Conditions
HIV Infections
Interventions
BIOLOGICAL

rgp120/HIV-1MN

BIOLOGICAL

rgp120/HIV-1 SF-2

Trial Locations (7)

14642

Univ. of Rochester ACTG CRS, Rochester

37232

Vanderbilt Univ. Hosp. AVEG, Nashville

63104

St. Louis Univ. School of Medicine AVEG, St Louis

98195

UW - Seattle AVEG, Seattle

Unknown

UAB AVEG, Birmingham

JHU AVEG, Pittsburgh

02115

Univ. of Rochester AVEG, Rochester

Sponsors

Collaborators (2)

Biocine
Genentech, Inc.
All Listed Sponsors
collaborator

Biocine

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00001031 - A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults | Biotech Hunter | Biotech Hunter